Artwork

المحتوى المقدم من The Radcliffe Cardiology Podcast. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة The Radcliffe Cardiology Podcast أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !

Ep 4: The EXCEL Trial: The Interventionalists’ Perspective

12:40
 
مشاركة
 

Manage episode 318823677 series 2990303
المحتوى المقدم من The Radcliffe Cardiology Podcast. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة The Radcliffe Cardiology Podcast أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Did you know that left main stem disease is identified in 5% of diagnostic angiography cases? The EXCEL trial was a randomised clinical trial published in 2019 which studied left main stem disease of low or intermediate complexity. The trial came under controversy due to its definition of MI, leading to a loss in patient and public trust, and a deterioration in the relationship between the cardiothoracic and PCI communities. In this month's featured author episode of the ECR Podcast, interventional fellow Dr George Hunter (Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK) discusses the EXCEL trial from his perspective as a member of the PCI community, based on a recent review paper: https://www.ecrjournal.com/articles/excel-trial-interventionalists-perspective?_ga=2.187238699.2063070761.1642409370-1520007507.1640163023 from the ECR Journal. In this podcast, Dr Hunter discusses the controversy surrounding the trial and the importance of studying left main stem disease in cardiology today. If you would like to learn more about the EXCEL Trial, view our special collection here: https://www.ecrjournal.com/special-collections/445/recent Episodes are released on the last Friday of each month. If you have any questions, please email managingeditor@ecrjournal.com.
  continue reading

43 حلقات

Artwork
iconمشاركة
 
Manage episode 318823677 series 2990303
المحتوى المقدم من The Radcliffe Cardiology Podcast. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة The Radcliffe Cardiology Podcast أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Did you know that left main stem disease is identified in 5% of diagnostic angiography cases? The EXCEL trial was a randomised clinical trial published in 2019 which studied left main stem disease of low or intermediate complexity. The trial came under controversy due to its definition of MI, leading to a loss in patient and public trust, and a deterioration in the relationship between the cardiothoracic and PCI communities. In this month's featured author episode of the ECR Podcast, interventional fellow Dr George Hunter (Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK) discusses the EXCEL trial from his perspective as a member of the PCI community, based on a recent review paper: https://www.ecrjournal.com/articles/excel-trial-interventionalists-perspective?_ga=2.187238699.2063070761.1642409370-1520007507.1640163023 from the ECR Journal. In this podcast, Dr Hunter discusses the controversy surrounding the trial and the importance of studying left main stem disease in cardiology today. If you would like to learn more about the EXCEL Trial, view our special collection here: https://www.ecrjournal.com/special-collections/445/recent Episodes are released on the last Friday of each month. If you have any questions, please email managingeditor@ecrjournal.com.
  continue reading

43 حلقات

كل الحلقات

×
 
Loading …

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

 

دليل مرجعي سريع